Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
J Pediatr. 2021 Aug;235:34-41.e1. doi: 10.1016/j.jpeds.2021.03.012. Epub 2021 Mar 16.
To evaluate the association of a combined exposure to antenatal steroids and prophylactic indomethacin with the outcome of spontaneous intestinal perforation (SIP) among neonates born at <26 weeks of gestation or <750 g birth weight.
We conducted a retrospective study of preterm infants admitted to Canadian Neonatal Network units between 2010 and 2018. Infants were classified into 2 groups based on receipt of antenatal steroids; the latter subgrouped as recent (≤7 days before birth) or latent (>7 days before birth) exposures. The co-exposure was prophylactic indomethacin. The primary outcome was SIP. Multivariable logistic regression analysis was used to calculate aORs.
Among 4720 eligible infants, 4121 (87%) received antenatal steroids and 1045 (22.1%) received prophylactic indomethacin. Among infants exposed to antenatal steroids, those who received prophylactic indomethacin had higher odds of SIP (aOR 1.61, 95% CI 1.14-2.28) compared with no prophylactic indomethacin. Subgroup analyses revealed recent antenatal steroids exposure with prophylactic indomethacin had higher odds of SIP (aOR 1.67, 95% CI 1.15-2.43), but latent antenatal steroids exposure with prophylactic indomethacin did not (aOR 1.24, 95% CI 0.48-3.21), compared with the respective groups with no prophylactic indomethacin. Among those not exposed to antenatal steroids, mortality was lower among those who received prophylactic indomethacin (aOR 0.45, 95% CI 0.28-0.73) compared with no prophylactic indomethacin.
In preterm neonates of <26 weeks of gestation or birth weight <750 g, co-exposure of antenatal steroids and prophylactic indomethacin was associated with SIP, especially if antenatal steroids was received within 7 days before birth. Among those unexposed to antenatal steroids, prophylactic indomethacin was associated with lower odds of mortality.
评估产前类固醇和预防性吲哚美辛联合暴露与<26 周胎龄或<750 克出生体重的新生儿自发性肠穿孔(SIP)结局的关系。
我们对 2010 年至 2018 年期间在加拿大新生儿网络单位住院的早产儿进行了回顾性研究。根据接受产前类固醇的情况将婴儿分为 2 组;后者亚组为近期(出生前≤7 天)或潜伏(出生前>7 天)暴露。共同暴露为预防性吲哚美辛。主要结局是 SIP。多变量逻辑回归分析用于计算 aOR。
在 4720 名符合条件的婴儿中,4121 名(87%)接受了产前类固醇,1045 名(22.1%)接受了预防性吲哚美辛。在接受产前类固醇的婴儿中,与未接受预防性吲哚美辛的婴儿相比,接受预防性吲哚美辛的婴儿 SIP 的可能性更高(aOR 1.61,95%CI 1.14-2.28)。亚组分析显示,近期产前类固醇暴露联合预防性吲哚美辛 SIP 的可能性更高(aOR 1.67,95%CI 1.15-2.43),而潜伏性产前类固醇暴露联合预防性吲哚美辛 SIP 的可能性较低(aOR 1.24,95%CI 0.48-3.21),与各自未接受预防性吲哚美辛的组相比。在未接受产前类固醇的婴儿中,与未接受预防性吲哚美辛的婴儿相比,接受预防性吲哚美辛的婴儿死亡率较低(aOR 0.45,95%CI 0.28-0.73)。
在<26 周胎龄或出生体重<750 克的早产儿中,产前类固醇和预防性吲哚美辛的联合暴露与 SIP 相关,尤其是如果产前类固醇在出生前 7 天内使用。在未接受产前类固醇的婴儿中,预防性吲哚美辛与较低的死亡率相关。